# Eli Lilly's diabetes and obesity drug Mounjaro has emerged as the world's top-selling medicine, overtaking Merck’s blockbuster cancer therapy Keytruda.

*biotech · news · 2026-05-07 · India Today*

## Key points

- Eli Lilly’s Mounjaro surpassed Merck’s Keytruda as the world’s top-selling medicine in 2026.
- Mounjaro generated $8.7 billion in global sales in Q1 2026, exceeding Keytruda’s $7.9 billion.
- Despite cheaper semaglutide generics, Mounjaro remains India’s highest-selling drug by value since October 2025.
- Combined tirzepatide portfolio sales for Lilly reached $36.5 billion in 2025, well above Keytruda’s $31.6 billion.
- Lilly views India as a high-growth market and potential export hub for Mounjaro.

**Companies:** Eli Lilly, Merck & Co
**Countries:** United States, India

[Read the full story on India Today](https://www.indiatoday.in/health/story/mounjaro-overtakes-keytruda-world-top-selling-drug-india-sales-surge-2908060-2026-05-07)

---

Canonical: https://newsio.io/n/f0cec181-f4dd-4fb1-9291-c2f4af4373ce/eli-lillys-diabetes-and-obesity-drug-mounjaro-has-emerged-as-the-worlds-top-sell
Summarized by Newsio from India Today. https://newsio.io/how-it-works